Astrazeneca Ab

Ratan Bhat

Stefan Berg

Sven Hellberg

James Empfield

James Woods

Philip L Edwards

Michael Thaddeus Klimas

Anna-Lena Berg

The present invention relates to a new use of a compound of the formula (I) 

Method of treatment of bone-related disorders or conditions

The present invention relates to new compounds of formula I wherein R, R, R, n, m are defined as in claim 1, a process for their preparation and new intermediates used in the preparation thereof, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy, especially in the prevention and/or treatment of dementia related diseases, Alzheimer's Disease and conditions associated with glycogen synthase kinase-3 

Compounds in the treatment of dementia related diseases, Alzheimer's Disease and conditions associated with glycogen synthase kinase-3

The present invention relates to new compounds of formula (I) wherein Y, P, R, R, R, n, m are defined as in claim, a process for their preparation and new intermediates used therein, pharmaceutical composition containing said therapeutically active compounds and to the use of said active compounds in therapy, especially in the prevention and/or treatment of dementia related disease, Alzheimer's Disease and conditions associated with glycogen synthase kinase-3 

Compounds for the treatment of dementia related diseases

An aqueous solution for prophylactic treatment of teats of lactating mammals, comprising as a first component at least partially deacetylated chitosan, or an acid addition salt thereof, in a concentration of up to about 2% by weight of chitosan, the solution having a pH of from about 4 to about 6.8, and said first component having a molecular weight such that the viscosity of the solution is less than about 50 mPas; and a method of prophylactic treatment of teats of lactating mammals.

Growing community of inventors

Södertälje, Sweden

Ratan Bhat